Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Orexin receptor type 1

3

Orexin receptor type 2

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2014

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Sleep-onset insomnia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck Sharp & Dohme

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

CHEBI

1

ChEMBL

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

HYPNOTICS AND SEDATIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other hypnotics and sedatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Suvorexant

081L192FO9

Export Data
Search for Structure

Status:

US Approved Rx (2014)

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Orexin receptor type 1

Orexin receptor type 2

Conditions:

Sleep-onset insomnia

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...

n receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Suvorexant, (±)-

28HD8972KE

Export Data
Search for Structure

Status:

US Approved Rx (2014)

First approved in 2014

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Orexin receptor type 1

Orexin receptor type 2

Conditions:

Sleep-onset insomnia

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...

n receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

SUVOREXANT HYDROCHLORIDE

5D3S2VQZ54

Export Data
Search for Structure

Status:

US Approved Rx (2014)

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Orexin receptor type 1

Orexin receptor type 2

Conditions:

Sleep-onset insomnia

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...

n receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1